Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Background: Antifibrotics are recommended for the treatment of individuals with idiopathic pulmonary fibrosis (IPF), but treatment use remains at ∼60%. Objective: To investigate the views of individuals with IPF and pulmonologists on the diagnosis and management of IPF to understand treatment patterns. Methods: Interviews and/or online surveys were completed by patients and pulmonologists from Canada, France, Germany, Italy, Spain, and the UK. Responses from physicians were analyzed by time between diagnosis and treatment initiation in the majority of patients with IPF (group A, > 4 months; group B, ≤4 months). Statistical comparisons between physicians were undertaken using z tests, with p < 0.05 considered statistically significant. Results: The physicians in group A saw fewer patients, were less comfortable discussing the IPF prognosis with patients, and had less belief in the benefits of antifibrotic treatments than the physicians in group B. These physicians’ attitudes contrasted with those of the patients, who wanted more information about the IPF prognosis and pharmacological treatment options at diagnosis and were more concerned about preventing disease progression than avoiding medication side effects. Differences between countries were found regarding physicians’ comfort in discussing the prognosis at diagnosis and access to care. Conclusions: Several barriers to antifibrotic treatment, principally reflecting the differing views and values of patients and physicians, were identified in this study, suggesting a need for better patient-physician communication about pharmacological therapy for IPF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
The rising incidence of idiopathic pulmonary fibrosis in the UK
Navaratnam, V., Fleming, K. M., West, J., Smith, C. J. P., Jenkins, R. G., Fogarty, A., & Hubbard, R. B. (2011) · Thorax · doi:10.1136/thx.2010.148031 · Cited by 484
Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Vancheri, C., Failla, M., Crimi, N., & Raghu, G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00077309 · Cited by 464
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Glasscock, K. F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207011 · Cited by 180
Self-citationAlbera, C., Costabel, U., Fagan, E. A., Glassberg, M. K., Gorina, E., Lancaster, L., Lederer, D. J., Nathan, S. D., Spirig, D., & Swigris, J. J. (2016) · European Respiratory Journal · doi:10.1183/13993003.01966-2015 · Cited by 166
Self-citationCommunication and patient participation influencing patient recall of treatment discussions
Richard, C., Glaser, E., & Lussier, M. (2017) · Health Expectations · doi:10.1111/hex.12515 · Cited by 154
European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers
Bonella, F., Wijsenbeek, M., Molina-Molina, M., Duck, A., Mele, R., Geissler, K., & Wuyts, W. (2016) · European Respiratory Journal · doi:10.1183/13993003.01204-2015 · Cited by 144
Self-citationCostabel, U., Bendstrup, E., Cottin, V., Dewint, P., Egan, J. J. J., Ferguson, J., Groves, R., Hellström, P. M., Kreuter, M., Maher, T. M., et al. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0112-1 · Cited by 138
Self-citation
Cited by
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
“IPF, access/reimbursement issues, and concerns over the adverse effects of antifibrotic drugs [47, 48] (Fig.”
BackgroundSelf-citationBehr, J., Prasse, A., Wirtz, H., Koschel, D., Pittrow, D., Held, M., Klotsche, J., Andreas, S., Claussen, M., Grohé, C., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02279-2019 · Cited by 198
Self-citationMaher, T. M., Kreuter, M., Lederer, D. J., Brown, K. K., Wuyts, W. A., Verbruggen, N., Stutvoet, S., Fieuw, A. M., Ford, P., Abi‐Saab, W., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000422 · Cited by 103
Self-citationEfficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Richeldi, L., Kolb, M., Jouneau, S., Wuyts, W. A., Schinzel, B., Stowasser, S., Quaresma, M., & Raghu, G. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-1030-4 · Cited by 96
Lee, J. Y. T., Tikellis, G., Corte, T. J., Goh, N. S. L., Keir, G. J., Spencer, L. M., Sandford, D., Khor, Y. H., Glaspole, I., Price, J., et al. (2020) · European Respiratory Review · doi:10.1183/16000617.0125-2019 · Cited by 91
Metadata
- Authors
- Maher, T. M., Swigris, J. J., Kreuter, M., Wijsenbeek, M., Cassidy, N., Ireland, L., Axmann, J., & Nathan, S. D.
- Affiliations
- Royal Brompton Hospital (GB)
- National Jewish Health (US)
- Heidelberg University (DE)
- Erasmus MC (NL)
- F. Hoffmann-La Roche AG (CH)
- Inova Fairfax Hospital (US)
- ORCID
- Venue
- Respiration
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 96
- Issue
- 6
- Pages
- 514-524
- ISSN
- 0025-7931 (ISSN-L)
- 1423-0356
- OpenAlex
- W2885464317
- Semantic Scholar
- 601dc0fbcc99d3a67390da0fe6c7502ad83884d7
- Cited by
- 69
- References
- 22
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 9 · 2023: 11 · 2022: 12 · 2021: 8 · 2020: 15 · 2019: 8 · 2018: 1
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Respiration (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- GlaxoSmithKline
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative Care and End-of-Life Issues
- Keywords
- idiopathic pulmonary fibrosis, antifibrotic therapy, barriers to treatment, patient-physician communication, physician attitudes, prognosis disclosure, treatment initiation timing, patient expectations, health care access, disease progression prevention, adverse drug reactions
- MeSH terms
- Pulmonologists, Adult, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Surveys and Questionnaires, Idiopathic Pulmonary Fibrosis, Watchful Waiting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. https://app.cochat.ai/papers/10.1159/000490667
- The paper
- Maher, T. M., Swigris, J. J., Kreuter, M., Wijsenbeek, M., Cassidy, N., Ireland, L., Axmann, J., & Nathan, S. D. (2018). Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. https://doi.org/10.1159/000490667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.